LifeMD has partnered with Eli Lilly to allow its affiliated pharmacy to dispense and ship Lilly's self-pay GLP-1 medications, Zepbound® and Foundayo®, directly to eligible patients across the U.S. Patients prescribed these medications by LifeMD providers can purchase them at Lilly's self-pay prices without using insurance. This integration enhances LifeMD's virtual care platform by combining consultation, prescribing, and medication delivery into a seamless experience, aiming to improve access to obesity treatments. Both companies plan to explore expanding access to more medicines in the future.
Eli Lilly And Co (LLY) shares are trading at USD 1,429.23, up 0.81% as of Nov 05, 2026 19:42 WIB on Pluang. The stock shows strong investor interest with 75% buy orders and a market cap of $1.26 trillion. This activity coincides with Lilly's expanding access to GLP-1 medications through LifeMD's platform, enhancing patient reach nationwide.
Phase 3 trials reveal retatrutide significantly reduces knee pain and weight in adults with knee osteoarthritis and obesity, with some patients pain-free by trial end. Additionally, a year-long study shows that combining Taltz and Zepbound improves d...
The National Advertising Division (NAD) recommended that Good Life Meds discontinue claims about health benefits and personalization for its compounded Tirzepatide+ weight loss products after a challenge by Eli Lilly. NAD found that Good Life lacked ...
Eli Lilly is positioned as a key beneficiary of AI in drug discovery, using its scale and research capabilities to speed up new molecule development and expand its product portfolio. Despite a high forward price-to-earnings ratio of 40, the company i...
Eli Lilly reported a 39% increase in revenue driven by a 53% rise in volume, despite a 15% decline in realized prices. The company's gross margin improved to 83.9%, reflecting strong operational efficiency. Most revenue comes from the obesity drug ti...
Eli Lilly reported a robust third quarter with revenue up 38.6% to $24.4 billion, driven by a 53% increase in tirzepatide volume. CEO David Ricks emphasized growth beyond weight-loss drugs, highlighting advances in immunology, oncology, and neuroscie...
